The health technology assessment agency has recommended in draft guidance that the antibody-drug conjugate be used on the NHS alongside bortezomib plus dexamethasone (BVd) as a second-line MM treatment for adults who are refractory to, or intolerant of, lenalidomide.
The decision means that eligible patients will be the first in the world to access the combination.
Approximately 6,240 cases of MM, an incurable blood cancer that develops in plasma cells in the bone marrow, are diagnosed in the UK each year. Despite available treatments, the disease often relapses or becomes resistant to standard care, with an estimated 64% of UK patients requiring second-line therapy…
